Under CAS Registry Number 84878-61-5, the veterinary-grade active ingredient is identified as maduramicin ammonium, the ammonium salt of the monocarboxylic polyether ionophore maduramicin isolated from the fermentation broth of a strain of Actinomadura. The substance has the reported molecular formula C₄₇H₈₃NO₁₇, corresponding to a relative molecular mass of approximately 934.15 g/mol. Potency is expressed in micrograms of maduramicin ammonium per milligram of dried substance rather than as a simple mass fraction, because the molecule is standardized against a reference standard with related substances controlled under the relevant antibiotic monograph to not more than 4.0% total. The principal approved veterinary indication is the prevention of intestinal coccidiosis in broiler chickens and turkeys caused by susceptible Eimeria spp. In finished feed, the compound is incorporated at 5–8 mg/kg complete feed depending on the jurisdiction; this inclusion concentration is between 10 and 25 times lower than those of monensin sodium or lasalocid sodium for the same target species.

For storage, the unmixed API requires sealed containers at controlled room temperature, protected from direct sunlight. Moisture accumulation above 5% w/w shifts particle morphology from free-flowing crystalline powder toward cohesive aggregates that compromise blend uniformity in low-inclusion premixes. Segregation of the ionic API during pneumatic conveying is a documented production risk in feed mills; batch homogeneity must therefore be revalidated whenever the carrier particle-size distribution or loading rate changes.

What Distinguishes Maduramicin Ammonium from Other Ionophore Anticoccidials?

Among the monovalent polyether ionophore subgroup, maduramicin ammonium suppresses coccidial proliferation by shuttling alkali metal cations across biological membranes and collapsing transmembrane electrochemical gradients in susceptible sporozoites and merozoites. The functional distinction from divalent ionophores such as lasalocid sodium lies in the narrower cation selectivity: maduramicin forms stable lipophilic complexes with sodium and potassium, whereas lasalocid additionally transports calcium and magnesium. This selectivity influences both the spectrum of coccidial suppression and the toxicity profile in non-target species.

The dose separation shown in Table 1 has direct consequences for premix manufacturing. Because maduramicin ammonium is added to finished feed at 5–8 mg/kg, a 1% premix achieves a working dilution of 1:1,250 to 1:2,000 when mixed into complete feed. Equivalent monensin premixes at 100–125 mg/kg inclusion require a 1:80 to 1:100 dilution. The wider dilution factor for maduramicin makes homogenous dispersion more sensitive to segregation during auger transfer and gravity flow in feed mills. Mixer uniformity studies for low-inclusion ionophore premixes routinely apply coefficient of variation acceptance thresholds of ≤5% across 10 sampling points when assayed by reversed-phase high-performance liquid chromatography with refractive index detection (Ph.Eur. 2.2.29).

Resistance patterns also differ. Eimeria field isolates with reduced sensitivity to monensin sodium may not exhibit complete cross-resistance to maduramicin ammonium because the ionophore binding cavity differs in steric geometry. However, published peer-reviewed data for this specific configuration is limited; alternating or shuttle programs between maduramicin and synthetic chemical coccidiostats are regulated at the national or regional level and are not universally specified.

For batch release of maduramicin veterinary API, compendial testing follows the antibiotic monograph framework. The substance is described as a white or off-white crystalline powder. Identification is confirmed by infrared absorption spectrophotometry (Ph.Eur. 2.2.24) against the current reference spectrum; where regional monographs differ, the stricter criterion is applied for batch release. Loss on drying is determined at 105°C to constant mass (Ph.Eur. 2.2.32), with acceptance specified at not more than 3.0% for the dried material. Residue on ignition, determined by the method of Ph.Eur. 2.4.16, is specified at not more than 0.5%. Heavy metals testing under the compendial general method applies a limit of not more than 20 ppm for total metal contamination. Assay is performed by high-performance liquid chromatography with refractive index detection because the molecule lacks a strong ultraviolet chromophore at wavelengths above 210 nm; the potency acceptance criterion is not less than 900 µg/mg on the anhydrous basis.

Residual solvent monitoring follows the current ICH Q3C guideline, with Class 2 solvents controlled to the permitted daily exposure limits and Class 3 solvents notified as present where manufacturing solvents include acetone or methanol. The API is tested against a standard of known potency in each analytical run; chromatographic system suitability requires resolution between maduramicin ammonium and its principal related substance of not less than 1.5, with relative standard deviation of replicate injections not exceeding 2.0%.

When Production Shifts from Low-Inclusion Premix to Direct Tablet Compression

For direct compression of maduramicin ammonium into tablets at veterinary dose strengths, the high potency of the API imposes specific dilution requirements. A single tablet containing 5 mg maduramicin ammonium would require a total tablet mass of 200 mg if formulated at 2.5% w/w drug load; direct blending of the unmixed API with excipients cannot reliably meet content uniformity acceptance criteria under Ph.Eur. 2.9.40 or USP <905> for such low proportions. The API is therefore first triturated geometrically with a diluent of similar particle-size distribution, typically lactose monohydrate or dibasic calcium phosphate dihydrate, at ratios of 1:10 in not fewer than three sequential steps. The resulting trituration is then combined with a disintegrant such as crospovidone and a lubricant such as magnesium stearate at 0.5% w/w. Final blend uniformity is verified by stratified sampling, with a target active content of 95–105% of label claim and a relative standard deviation of ≤5%.

Tablet compression is performed on a rotary tablet press equipped with an instrumented precompression station. Because maduramicin ammonium is light-sensitive, the compression suite uses amber light filtration; prolonged exposure of loose powder to white fluorescent lighting between blending and compression is avoided. Hardness testing per Ph.Eur. 2.9.8 is applied to confirm tablet integrity, while disintegration testing per Ph.Eur. 2.9.1 verifies release characteristics. The finished tablets are stored in amber high-density polyethylene containers with desiccant to maintain moisture below 5% RH-equivalent.

For capsules, the trituration approach is retained. The powder blend is filled into hard gelatin capsules using a dosator-type capsule filler; the fill weight is controlled to ±5% on an in-process balance. Capsule content uniformity is assessed according to Ph.Eur. 2.9.40. The filled capsules are packaged in amber glass containers with desiccant.

Given that maduramicin ammonium is classified as practically insoluble in water, injectable presentations require non-aqueous vehicles rather than simple aqueous reconstitution. Under the pharmacopeial descriptive solubility system, more than 10,000 mL of water is required to dissolve 1 g of solute at 20°C. Injectable formulations in non-aqueous vehicles such as propylene glycol, polyethylene glycol 300, or ethanol–water co-solvent mixtures have been described in technical bulletins, but published peer-reviewed data for this specific configuration is limited. For drinking-water administration, the API is predisolved in a water-miscible solvent and then diluted into the drinking-water system. The resulting mixture may be a true solution only in the co-solvent phase; upon aqueous dilution, the API tends to form a microcrystalline dispersion or micellar suspension rather than a thermodynamically stable solution.

Stability of diluted aqueous preparations is pH-dependent. The polyether backbone is subject to accelerated hydrolysis at pH values below 5; working dilutions are therefore buffered to near-neutral pH where prolonged storage is anticipated. Ultraviolet exposure accelerates degradation; solution reservoirs and injection vials are protected with opaque or amber glass. Prepared dilutions are used within 24 hours when stored at ambient temperature, or within 72 hours under refrigeration at 2–8°C.

Cross-Contamination Carryover Thresholds in Multi-Ionophore Feed Mills

In feed mills operating shared equipment, the narrow therapeutic index of maduramicin ammonium imposes strict segregation requirements. Documented equine mortalities following ingestion of maduramicin-contaminated feed have placed the compound among the highest-risk ionophore active substances for cross-contamination management. Feed mills handling maduramicin premix implement dedicated or physically separated production lines; where shared lines are unavoidable, validated cleanout procedures are required. Cleanout is verified by analytical testing at a limit of quantification not exceeding 0.1 mg/kg in the subsequent batch of finished feed. The use of flush batches is documented in batch records, and equipment teardown includes removal of dead-space zones in bucket elevators, drag conveyors, and mixer discharge gates.

Cleaning validation follows the principles of EU GMP Annex 15 and the FAMI-QS Code of Practice, with acceptance limits calculated from the therapeutic dose of the subsequent product and the toxicological limit for the most sensitive species. Swab sampling points are selected according to worst-case locations identified during riboflavin coverage studies using 365 nm ultraviolet illumination. Carryover is expressed in parts per million of the contaminating ionophore in the next batch; for equine-sensitive sites, the internal carryover limit is set below 0.5% of the therapeutic dose of maduramicin, which translates to values in the low microgram-per-kilogram range. Published data for this specific configuration is limited, but the control ranges are derived from the known equine toxicity observations.

To produce a granulated intermediate with acceptable flow and low dusting, maduramicin API is processed in a fluidized bed granulator with the milled active dispersed in a binder solution of povidone K-30 at 5% w/w solids. Inlet air temperature is maintained below 60°C, and product bed temperature is monitored continuously to avoid localized thermal stress. Loss on drying of the finished granules is specified at not more than 5% w/w to suppress microbial growth and caking. The particle-size distribution is optimized for flowability and blend uniformity; retained oversized material is milled through a low-shear cone mill to preserve granule integrity.

Premix manufacturing proceeds through a geometric dilution sequence. The API or granulated intermediate is combined with a carrier such as calcium carbonate, ground rice hulls, or corncob meal in a ribbon blender or double-shaft paddle mixer. The sequence proceeds in ratios of 1:10 at each step until the target premix concentration of 1% or 2% w/w maduramicin ammonium is achieved. Mixing time is validated for each equipment configuration using the marker assay; a coefficient of variation ≤5% across 10 stratified sampling points is the common in-process acceptance threshold. The finished premix is packaged in multiwall paper bags with a polyethylene liner to maintain moisture protection.